CpG island methylator phenotype in adenocarcinomas from the digestive tract: Methods, conclusions, and controversies

Table 3 Comparison between our CpG island methylator phenotype classification of stomach adenocarcinomas and the four subtypes defined by The Cancer Genome Atlas Research Network¹

	CIN	EBV+	GS	MSI	Total
CIMP+	212 (26.6)	313 (5.4)	22 (11.3)	327 (10.7)	-54
CIMPi	43 (45.75)	12 (9.4)	20 (19.5)	18 (18.4)	93
CIMP-	367 (49.68)	20 (10.2)	330 (21.2)	24 (20.0)	101
Total	122	25	52	49	248

¹Numbers outside parentheses correspond to actual sample counts, whereas numbers in parentheses show expected counts under the null model of independent classification;

²Indicates under-represented counts;

³Indicates cells with significantly over-represented counts (P < 0.05, based on Fisher’s exact test). CIMP: CpG island methylator phenotype; CIMPi: CIMP intermediate; CIN: Chromosomal instability; EBV+: Epstein-Barr virus positive; GS: Genomically stable; MSI: Microsatellite instability.